New Nature Neuroscience data shows MCU inhibition blocks drug reward without touching natural reward circuits, a mechanistic breakthrough for...

Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division reshapes Phase I site networks and vendor contracts for sponsors...

Nature Reviews Drug Discovery identifies SLC transporters as untapped CNS drug targets, but 97% remain undrugged, and trial designers...

Tekton Research sites enrolled 60 participants in Phase 2 obesity trial, tripling their combined enrollment goal and demonstrating strong...

Myriad bioscaffolds demonstrated a 0.7% deep infection rate in soft tissue reconstruction across 411 patients, significantly below historical benchmarks.

Clover's RSV-hMPV vaccine produced 6-to-9-fold antibody rises in Phase 2, with no immune interference and strong safety. Candidate targets...

FDA guidance expands cancer trial eligibility to include patients with ECOG PS 2, reshaping enrollment models and operational requirements...

Signant Health and Lothar Medical plan integrated respiratory trial device combining spirometry, oscillometry, and FeNO measurement into a single...

Canada's drug agency recommends conditional reimbursement for palopegteriparatide in hypoparathyroidism, pending price negotiation and provincial formulary deci

Roivant presents Phase 2 mosliciguat data for PH-ILD, measuring pulmonary vascular resistance changes over 24 weeks in a 135-patient...